NcXHF

NOVEL TREATMENTS FOR T-CELL LYMPHOMA
tients with adult T-cell leukemia-lymphoma and peripheral T-cell
lymphoma. J Clin Oncol. 2010;28:1591-1598.
43. Ogura M, Ishida T, Hatake K, et al. Multicenter phase II study of mogamulizumab
(KW-0761), a defucosylated anti-cc chemokine receptor 4
antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous
T-cell lymphoma. J Clin Oncol. 2014;32:1157-1163.
44. Zinzani PL, Coiffıer B, Radford J, et al. A phase II open-label multicenter
study of anti-CCR4 monoclonal antibody mogamulizumab
(KW-0761) in patients with previously treated peripheral T-cell lymphoma
(PTCL) [abstract]. Blood. 2014;124:1763.
45. Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal
antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a
multicenter phase II study. J Clin Oncol. 2012;30:837-842.
46. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone
for relapsed multiple myeloma in North America. N Engl J Med.
2007;357:2133-2142.
47. Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy
in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin
Oncol. 2008;26:4952-4957.
48. Morschhauser F, Fitoussi O, Haioun C, et al. A phase 2, multicentre,
single-arm, open-label study to evaluate the safety and effıcacy of singleagent
lenalidomide (Revlimid) in subjects with relapsed or refractory
peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial. Eur J
Cancer. 2013;49:2869-2876.
49. Toumishey E, Prasad A, Dueck G, et al. Final report of a phase 2 clinical
trial of lenalidomide monotherapy for patients with T-cell lymphoma.
Cancer. Epub 2014 Oct 29.
50. Zinzani PL, Pellegrini C, Broccoli A, et al. Lenalidomide monotherapy
for relapsed/refractory peripheral T-cell lymphoma not otherwise specifıed.
Leuk Lymphoma. 2011;52:1585-1588.
51. Hamada M, Yakushijin Y, Ohtsuka M, et al. Aurora2/BTAK/STK15 is
involved in cell cycle checkpoint and cell survival of aggressive non-
Hodgkin’s lymphoma. Br J Haematol. 2003;121:439-447.
52. Manfredi MG, Ecsedy JA, Chakravarty A, et al. Characterization of Alisertib
(MLN8237), an investigational small-molecule inhibitor of aurora
A kinase using novel in vivo pharmacodynamic assays. Clin Cancer
Res. 2011;17:7614-7624.
53. Friedberg JW, Mahadevan D, Cebula E, et al. Phase II study of alisertib,
a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive
B- and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2014;32:44-
50.
54. Barr PM, Li H, Spier CM, et al. U.S. intergroup phase II trial (SWOG
1108) of alisertib, an investigational aurora A kinase (AAK) inhibitor, in
patients with peripheral T-cell lymphoma (PTCL; NCT01466881).
J Clin Oncol. 2014;32:5s (suppl; abstr 8523).
55. Fanale MA, Horwitz SM, Forero-Torres A, et al. Brentuximab vedotin
in the front-line treatment of patients with CD30 peripheral T-cell
lymphomas: results of a phase I study. J Clin Oncol. 2014;32:3137-3143.
56. Advani R, Ansell SM, Lechowicz MJ, et al. A phase II study of cyclophosphamide,
etoposide, vincristine and prednisone (CEOP) alternating
with pralatrexate (P) as front line therapy for patients with peripheral
T-cell lymphoma (PTCL): preliminary results from the T-cell Consortium
trial [abstract]. Blood. 2013;122:3044.
57. Dupuis J, Morschhauser F, Ghesquieres H, et al. Final analysis of the
RO-CHOP phase Ib/II study: romidepsin in association with CHOP in
patients with peripheral T-cell lymphoma (PTCL) [abstract]. Blood.
2014;124:504.
58. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide
hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma
(CTCL). Blood. 2007;109:31-39.
59. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat
in patients with persistent, progressive, or treatment refractory
cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109-3115.
60. Oki Y, Younes A, Copeland A, et al. Phase I study of vorinostat in combination
with standard CHOP in patients with newly diagnosed peripheral
T-cell lymphoma. Br J Haematol. 2013;162:138-141.
61. Binder C, Ziepert M, Pfreundschuh M, et al. CHO(E)P-14 followed by
alemtuzumab consolidation in untreated peripheral T cell lymphomas:
fınal analysis of a prospective phase II trial. Ann Hematol. 2013;92:1521-
1528.
62. Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (Campath-1H) and
CHOP chemotherapy as fırst-line treatment of peripheral T-cell lymphoma:
results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi)
prospective multicenter trial. Blood. 2007;110:2316-2323.
63. Kluin-Nelemans HC, van Marwijk Kooy M, Lugtenburg PJ, et al. Intensifıed
alemtuzumab-CHOP therapy for peripheral T-cell lymphoma.
Ann Oncol. 2011;22:1595-1600.
64. Hopfınger G, Nösslinger T, Lang A, et al. Lenalidomide in combination
with vorinostat and dexamethasone for the treatment of relapsed/refractory
peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
Ann Hematol. 2014;93:459-462.
65. Goh Y-T, Hwang WY, Diong CP, et al. A Phase 2 study of panobinostat
(PAN) in combination with bortezomib (BTZ) in patients with relapsed/refractory
peripheral T-cell lymphoma (PTCL) or NK/T-cell
lymphoma (NKL) [abstract]. Blood. 2014;124:503.
66. Zullo K, Guo Y, Cooke L, et al. The investigational Aurora A kinase
inhibitor alisertib exhibits broad activity in preclinical models of T-cell
lymphoma and is highly synergistic with romidepsin [abstract]. Blood.
2014;124:4493.
67. Fanale MA, Hagemeister FB, Fayad L, et al. A phase I trial of alisertib
plus romidepsin for relapsed/refractory aggressive B- and T-cell lymphomas
[abstract]. Blood. 2014;124:1744.
68. Lunning MA, Ruan J, Nair S, et al. A phase I/II trial of the combination
of romidepsin and lenalidomide in patients with relapsed/refractory
lymphoma and myeloma: phase I results. J Clin Oncol. 2014;32:5s
(suppl; abstr 8582).
69. Horwitz SM, Porcu P, Flinn I, et al. Duvelisib (IPI-145), a
phosphoinositide-3-kinase-, inhibitor, shows activity in patients with
relapsed/refractory T-cell lymphoma [abstract]. Blood. 2014;124:803.
70. Vakkalanka S, Viswanadha S, Govindarajulu B, et al. Therapeutic potential
of dual PI3K/ inhibition in T-cell lymphomas. Presented at the
European Hematology Association (EHA) Meeting, June 2013 Stockholm,
Sweden.
71. Scarfò L, Barde PJ, Fazi C, et al. A phase I dose escalation study of
RP6530, a novel, dual PI3K- inhibitor, for patients with relapsed or
refractory hematologic malignancies [abstract]. Blood. 2014;124:3043.
72. Qian C, Lai CJ, Bao R, et al. Cancer network disruption by a single molecule
inhibitor targeting both histone deacetylase activity and phosphatidylinositol
3-kinase signaling. Clin Cancer Res. 2012;18:4104-4113.
73. Zinzani PL, Musuraca G, Tani M, et al. Phase II trial of proteasome inhibitor
bortezomib in patients with relapsed or refractory cutaneous
T-cell lymphoma. J Clin Oncol. 2007;25:4293-4297.
74. Kim SJ, Yoon DH, Kang HJ, et al. Bortezomib in combination with
CHOP as fırst-line treatment for patients with stage III/IV peripheral
T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Eur J Cancer.
2012;48:3223-3231.
75. Sasaki M, Knobbe CB, Munger JC, et al. IDH1(R132H) mutation increases
murine haematopoietic progenitors and alters epigenetics.
Nature. 2012;488:656-659.
76. Yang H, Ye D, Guan KL, et al. IDH1 and IDH2 mutations in tumorigenesis:
mechanistic insights and clinical perspectives. Clin Cancer Res.
2012;18:5562-5571.
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK
e477